Post-Conference Perspectives: Managing R/R B-ALL with CAR T-Cell Therapy

Jae Park, MD, reviews key data in the management of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) recently presented at the ASCO 2023 Annual Meeting.

EP. 1: Signs and Symptoms of B-Cell Acute Lymphoblastic Leukemia (B-ALL)

August 22nd 2023

Jae Park, MD, explains how B-cell acute lymphoblastic leukemia is diagnosed, and the testing done for detection of genetic abnormalities, which impacts treatment and prognosis.

EP. 2: Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL

August 22nd 2023

Dr Jae Park details the treatment options for relapsed/refractory B-cell acute lymphoblastic leukemia, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, with the treatment choice dependent on patient factors like comorbidities, disease burden, and transplant status.

EP. 3: R/R B-ALL: Key Efficacy Outcomes From the Updated Analysis of the ZUMA-3 Trial

August 30th 2023

Jae Park, MD, reviews updated data from the ZUMA-3 trial on the use of the CAR T-cell therapy brexucabtagene autoleucel (brexu-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia, noting high remission rates, management of side effects like cytokine release syndrome, and post-CAR-T consolidation, including transplant.

EP. 4: R/R B-ALL: Key Safety Outcomes From the Updated Analysis of the ZUMA-3 Trial

August 30th 2023

Dr Jae Park discusses managing cytokine release syndrome and the neurotoxicity side effects of CAR T-cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia through medications, disease burden reduction, and earlier intervention to prevent severe toxicities.

EP. 5: Outcomes Data Following Brexucabtagene Autoleucel Therapy in Patients With R/R B-ALL

September 6th 2023

Jae Park, MD, explains how real-world CAR T-cell therapy data in patients with relapsed/refractory B-cell acute lymphoblastic leukemia shows high response rates but emphasizes the ongoing need for optimizing toxicity management, with trends toward earlier treatment and cell collection.

EP. 6: An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice

September 6th 2023

Dr Jae Park shares his experience with using brexucabtagene autoleucel for patients with relapsed/refractory B-cell acute lymphoblastic leukemia in clinical practice since its FDA approval in October 2021.

EP. 7: The Future of R/R B-ALL Treatment

September 13th 2023

Jae Park, MD, wraps up his discussion by highlighting exciting investigational agents on the horizon for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.